Spravato® (Esketamine) Therapy for Depression
Spravato® at Graceland Psychiatry is an FDA-approved breakthrough treatment for adults battling Treatment-Resistant Depression. Administered as a nasal spray alongside an oral antidepressant, Spravato® works differently from traditional medications by targeting the brain's glutamate system offering rapid relief where other treatments have failed.
Clinical studies show over 60% of patients experience significant improvement, with 52% achieving full remission, all with minimal side effects.
Who Can Benefit from Spravato® at Graceland Psychiatry?
Spravato® is FDA-approved to treat two specific forms of depression in adults, especially when traditional antidepressants have failed to provide relief:
Treatment-Resistant Depression (TRD)
If you've tried two or more antidepressants at the right dose and duration without noticeable improvement, you may be experiencing treatment-resistant depression. Spravato® offers a new path forward by working differently from standard medications, often producing results within days.
Major Depressive Disorder with Suicidal Ideation
For adults struggling with major depressive disorder (MDD) who also experience suicidal thoughts or behaviors, Spravato® may serve as a powerful, fast-acting option. Administered in our safe and supportive clinical setting, this treatment can help stabilize symptoms and restore hope during critical moments.
